Overall, ventilator-associated pneumonia (32%) and hypotension requiring pressors (32%) were the most frequently encountered complications during cIV-PTB treatment, followed by urinary tract infection (13%), deep venous thrombosis (10%) and ileus (10%).
The outcomes assessed were: overall mortality, ventilator-free days, time of mechanical ventilation, adverse events, changes in gas exchange, in ventilator settings, and in respiratory mechanics.
The outcomes assessed were: overall mortality, ventilator-free days, time of mechanical ventilation, adverse events, and changes in gas exchange, in ventilator settings, and in respiratory mechanics.
Clinical outcome measures were overall survival, ventilator-free survival, left ventricular mass index, Alberta Infant Motor Scale score, and urine Glc(4) levels.Clinical outcomes in the high-titer crossreactive immunologic material-positive group were poor across all areas evaluated relative to the low-titer crossreactive immunologic material-positive group.
With regards to the overall patient-ventilator interaction, a low NeuroSync index and little inter-individual variability, confirms the effectiveness of PSN to synchronize assistance in the presence of PEEPi.
The efficacy of enzyme replacement therapy (ERT) with recombinant human GAA was demonstrated during clinical trials that prolonged subjects' overall survival, prolonged ventilator-free survival, and also improved cardiomyopathy, which led to broad-label approval by the U.S. Food and Drug Administration.
Secondary outcomes were the overall incidence of ventilator-associated pneumonia, unsuccessful extubation rates and ICU mortality.
The overall risk for ventilator-associated pneumonia (VAP) is between 9.7% and 22.8% [ 2].
Further, multiple trials of probiotics now demonstrate significant reductions in overall infections, including ventilator-associated pneumonia in the ICU [ 9, 10].
